HeartBeam (NASDAQ:BEAT) Announces Quarterly Earnings Results

HeartBeam (NASDAQ:BEAT) announced its quarterly earnings results on Thursday. The medical research company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.04, FiscalAI reports.

Here are the key takeaways from HeartBeam’s conference call:

• Heart attack detection advanced toward U.S. FDA review. HeartBeam reported that its 132-patient ALIGN-ACS study showed similar overall diagnostic accuracy to a standard 12-lead ECG, and said FDA discussions support a 510(k) pathway. The U.S. pivotal study is still being finalized, with enrollment targeted for late 2026 or Q1 2027.
• The company completed enrollment ahead of schedule in its 486-patient HEADSTART-ACS study, with results expected at a cardiology conference in 2027. It also reported progress on its AI program, while stressing that heart attack AI results are preliminary, internal, and not FDA-cleared.
• Spending and cash outflow declined. Q3 operating expenses fell 35% year over year to $3.5 million, and operating cash use dropped 18% to $2.6 million. HeartBeam reported about $10.1 million in pro forma cash after raising roughly $4 million after quarter-end and lowered its 2026 operating cash-outflow outlook to $12–$12.5 million.
• The company remains pre-commercial for its heart attack assessment product, and FDA study design, clearance timing, reimbursement, and broader commercialization are not yet assured. Management expects a Nasdaq compliance extension and says it is pursuing organic compliance, while noting that future funding needs and potential dilution remain considerations.

HeartBeam Stock Performance

HeartBeam stock traded down $0.01 during mid-day trading on Thursday, hitting $0.40. 434,550 shares of the company traded hands, compared to its average volume of 2,969,533. HeartBeam has a one year low of $0.35 and a one year high of $4.00. The stock has a market cap of $22.75 million, a price-to-earnings ratio of -0.79 and a beta of -0.84. The stock has a fifty day moving average price of $0.43 and a 200-day moving average price of $0.82.

Wall Street Analysts Forecast Growth

BEAT has been the topic of a number of recent analyst reports. Wall Street Zen upgraded HeartBeam to a “sell” rating in a research report on Saturday, October 10th. Weiss Ratings upgraded HeartBeam from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. Finally, HC Wainwright restated a “neutral” rating on shares of HeartBeam in a research note on Tuesday, October 6th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $4.00.

HeartBeam Company Profile

HeartBeam, Inc. is a medical technology company developing portable and digital solutions for cardiac monitoring. Its proprietary technology is designed to capture, analyze and transmit electrocardiogram (ECG) data outside traditional clinical settings, with a focus on helping identify cardiac events such as atrial fibrillation and heart attacks. The company’s flagship product is the HeartBeam AIMIGo system, which combines a compact, credit-card-sized ECG device with a smartphone application. The system is designed to record a three-dimensional, vector-based ECG and securely share the results with healthcare professionals for review.